TheraCryf (LSE:TCF) YoY EBITDA Growth : 37.50% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is TheraCryf YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TheraCryf's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 37.50%.

TheraCryf's EBITDA per Share for the six months ended in Sep. 2023 was £-0.01.

TheraCryf YoY EBITDA Growth Historical Data

The historical data trend for TheraCryf's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf YoY EBITDA Growth Chart

TheraCryf Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

YoY EBITDA Growth

Get a 7-Day Free Trial

15.79

25.00

12.50

42.86

-50.00

TheraCryf Semi-Annual Data
	Mar13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
YoY EBITDA Growth	Get a 7-Day Free Trial															57.14	25.00	-33.33	-66.67	37.50

TheraCryf YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TheraCryf's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

	YoY EBITDA Growth (A: Mar. 2023 )
=	(EBITDA per Share (A: Mar. 2023 )	-	EBITDA per Share (A: Mar. 2022 ))	/	\| EBITDA per Share (A: Mar. 2022 ) \|
=	(-0.018	-	-0.012)	/	\| -0.012 \|
=	-50.00 %

TheraCryf's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2023 )
=	(EBITDA per Share (Q: Sep. 2023 )	-	EBITDA per Share (Q: Sep. 2022 ))	/	\| EBITDA per Share (Q: Sep. 2022 )) \|
=	(-0.005	-	-0.008)	/	\| -0.008 \|
=	37.50 %

TheraCryf YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of TheraCryf's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

TheraCryf (LSE:TCF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

8EV:Germany

Address

Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG

Website

https://www.evgen.com

Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.